Cargando…

THU054 A Post Hoc Analysis Of The Phase IV B2219 Study To Determine Predictive Factors For Hyperglycemia During Treatment With Pasireotide

Disclosure: S.L. Samson: Consulting Fee; Self; Novartis Pharmaceuticals, Chiasma. M. Bolanowski: Grant Recipient; Self; Amryt, Recordati, Pfizer, Inc., Novartis Pharmaceuticals, Ipsen, IBSA, Teva Pharmaceutical Industries Ltd., Berlin Chemie. Speaker; Self; Amryt, Recordati, Pfizer, Inc., Novartis P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samson, Susan Leanne, Bolanowski, Marek, Zhang, Shao-Ling, Yu, Yerong, Witek, Przemysław, Kietsiriroje, Noppadol, Piacentini, Andrea, Pedroncelli, Alberto M, Feldt-Rasmussen, Ulla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Neuroendocrinology And Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553625/ http://dx.doi.org/10.1210/jendso/bvad114.1134

Ejemplares similares

MON-LB079 A Multicenter, Randomized, Open-Label, Phase IV Study Investigating Management of Pasireotide-Associated Hyperglycemia with Incretin-Based Therapy or Insulin in Patients with Acromegaly or Cushing's Disease (CD)
por: Samson, Susan, et al.
Publicado: (2019)

THU066 An 8-year Interim Report Of The B2412 Study, An Open-label, Multicenter Pasireotide Rollover Study For Patients Who Continued To Receive Benefit From Pasireotide At Completion Of An Earlier Trial
por: Gadelha, Mônica, et al.
Publicado: (2023)

Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study
por: Samson, Susan L., et al.
Publicado: (2021)

THU032 Osilodrostat Is Effective And Well Tolerated In Patients Of Asian And Non-Asian Origin With Cushing's Disease: A Pooled Analysis From LINC 3 And LINC 4
por: Snyder, Peter J, et al.
Publicado: (2023)

THU038 Osilodrostat Dosing In Cushing’s Disease: A Pooled Analysis Of The LINC Program
por: Newell-Price, John, et al.
Publicado: (2023)

THU027 Challenges In The Management Of Extreme Hyperglycemia In An Acromegalic Patient
por: Sonbol, Mark, et al.
Publicado: (2023)

THU041 Clinical Improvements In Patients With Cushing’s Disease Treated With Osilodrostat According To Urinary And Late-night Salivary Cortisol Levels: Pooled Analysis From LINC 3 And LINC 4
por: Biller, Beverly M K, et al.
Publicado: (2023)

PMON162 Osilodrostat Provides Sustained Clinical Benefits and Improves Health-Related Quality of Life in Patients with Cushing's Disease: Results from the Phase III LINC 4 Study
por: Feelders, Richard, et al.
Publicado: (2022)

THU120 Validation Of A Novel Automated System, Fluispotter®, For Serial Sampling Of Dried Blood Spots
por: Krogh, Jesper, et al.
Publicado: (2023)

SAT-305 Veldoreotide (COR005) Mechanisms of Action Studies: Comparison to Octreotide and Pasireotide
por: Dasgupta, Pooja, et al.
Publicado: (2020)

THU025 Acromegaly And Central Hyperthyroidism
por: Akhtar, Ahmad, et al.
Publicado: (2023)

THU096 When TSH Alone Is Not Enough
por: Awasty, Sanjana S, et al.
Publicado: (2023)

THU021 Mysterious Resolution Of Cushing’s Disease
por: Whiteman, Daniel R, et al.
Publicado: (2023)

MON-445 Long-Term Results of an Ongoing Non-Interventional, Real-World Observational Study of Pasireotide SC in Cushing's Disease
por: Yuen, Kevin, et al.
Publicado: (2019)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

THU022 A Case Of Delayed Diagnosis Of Acromegaly
por: Blanchard, Kayla, et al.
Publicado: (2023)

Real-World Experience With Pasireotide Lar in Acromegaly Resistant to First-Generation Somatostatin Analogs: A Single Center 1-Year Observation
por: Stelmachowska-Banas, Maria, et al.
Publicado: (2021)

THU017 Severe Hypercortisolemia- A Biological Time Bomb
por: Munasinghe, Uthpala, et al.
Publicado: (2023)

THU065 Evaluation Of Sarcopenia And Bone Health In Patients With Acromegaly
por: Eroglu, Imdat, et al.
Publicado: (2023)

THU030 Evaluation Of Combined CRH And HDDST Test Performance
por: Elenius, Henrik, et al.
Publicado: (2023)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

MON-460 Pasireotide Treatment Inhibits Cytokine Release from Pituitary Adenoma-Associated Fibroblasts: Is This Mechanism Playing a Key Role in Its Effect?
por: Marques, Pedro, et al.
Publicado: (2019)

MON-309 Prevalence of Silent Corticotroph Adenomas in a Large Cohort of Nonfunctioning Pituitary Adenomas: Plasma Proopiomelanocortin(POMC) Levels and Response to Pasireotide LAR
por: Reyes-Vidal, Carlos, et al.
Publicado: (2020)

THU109 An Interesting Case Of Infiltrative Panhypopituitarism Due To Metastatic Melanoma
por: Arora, Neha, et al.
Publicado: (2023)

THU121 Dopamine Regulates Neuroendocrine Cell Expansion In The Developing Lung
por: Watanabe, Takuya, et al.
Publicado: (2023)

THU111 Diffuse Large B-Cell Lymphoma Pituitary Metastasis
por: Martinez Cruz, Maria S, et al.
Publicado: (2023)

THU098 Gonadotropin Secreting Pituitary Tumor Presenting As Primary Hypogonadism
por: Shapiro, Joshua Nathan, et al.
Publicado: (2023)

THU015 Unilateral Adrenal Hyperplasia Causing ACTH-independent Hypercortisolism
por: Mogar, Nikita, et al.
Publicado: (2023)

THU009 Subclinical Cushing’s Syndrome In An ACTH-secreting Pituitary Macroadenoma
por: Akabogu, Nwamaka Gloria, et al.
Publicado: (2023)

PMON163 Effect of Osilodrostat on Androgens and Adrenal Hormones in Patients With Cushing's Disease: Long-Term Findings From the Phase III, Prospective LINC 3 Study
por: Fleseriu, Maria, et al.
Publicado: (2022)

SAT-LB076 T2-Signal Intensity, SST Receptor Expression and First-Generation Somatostatin Analogues Efficacy Predict Hormone and Tumor Responses to Pasireotide in Acromegaly
por: Coopmans, Eva, et al.
Publicado: (2019)

THU087 Natural History Of Nonfunctioning Pituitary Macroadenomas Followed Without Intervention
por: Ayalon-Dangur, Irit, et al.
Publicado: (2023)

THU114 Postsurgical Use Of Copeptin In The Prediction Of Postoperative Arginine Vasopressin Deficiency
por: Erickson, Dana Z, et al.
Publicado: (2023)

THU117 Lipocalin-2 As A Mediator Of Negative Affect After Sepsis
por: Yang, Shany E, et al.
Publicado: (2023)

THU104 An Atypical Case Of A Suprasellar Cyst: A Diagnostic Challenge
por: Chen, Ana, et al.
Publicado: (2023)

THU051 GH Resistance And Adipose Tissue: Multispecies Measurement Of Morphology And Transcriptome
por: Young, Jonathan A, et al.
Publicado: (2023)

THU040 Different Patient Versus Provider Perspectives On Living With Cushing’s Disease
por: Halstrom, Amanda, et al.
Publicado: (2023)

PMON160 Improvements in Clinical Signs of Hypercortisolism and Quality of Life According to Urinary and Late-Night Salivary Cortisol Levels in Patients with Cushing's Disease Treated with Osilodrostat
por: Biller, Beverly M K, et al.
Publicado: (2022)

THU100 Case Of A Large Suprasellar-clival Mass: Prolactinoma Vs Paraganglioma
por: Madera Marin, Luis Norberto, et al.
Publicado: (2023)

THU116 Characteristics Of Sleep Disturbance And The Related Hormonal Changes In Patients With Long COVID
por: Sunada, Naruhiko, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ma8lfkej18e03243l0ig5i6hs1